Skip to main content

Table 3 Relationship between CDK gene expression and HCC prognosis in TCGA cohort

From: Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma

Variables

Patient (n = 370)

OS

No. of events

MST (days)

HR (95% CI)

P

Adjusted HR (95% CI)

Adjusted Pa

CDK1

       

 LOW

185

53

2131

1

 

1

 

 HIGH

185

77

1149

1.796 (1.265–2.551)

0.001

1.541 (1.048–2.266)

0.028

CDK2

       

 LOW

185

61

2116

1

 

1

 

 HIGH

185

69

1490

1.450 (1.025–2.051)

0.036

1.305 (0.896–1.900)

0.165

CDK3

       

 LOW

185

65

13,786

1

 

1

 

 HIGH

185

65

1852

0.775 (0.534–1.067)

0.111

0.934 (0.640–1.363)

0.723

CK4

       

 LOW

185

54

2456

1

 

1

 

 HIGH

185

76

1229

1.779 (1.253–2.526)

0.001

1.721 (1.179–2.513)

0.005

CDK6

       

 LOW

185

66

1624

1

 

1

 

 HIGH

185

64

1852

1.042 (0.738–1.471)

0.815

1.068 (0.733–1.554)

0.733

  1. OS, overall survival; MST, median survival time; HR, hazard ratio; CI, confidence interval
  2. aAdjusted for tumor stage and radical resection